Drug Trial Radar · NCT05092347
A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)
Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
43
Actual
Start
Aug 2, 2022
Primary completion
Nov 22, 2027
Study completion Nov 22, 2027
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Oct 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether vonsetamig will safely decrease anti-HLA antibodies to allow for kidney transplantation. Vonsetamig is being studied for treatment of patients in need of kidney transplantation who are highly sensitized to HLA. The study is looking at several other research questions, including: * Side effects that may be experienced from taking vonsetamig * How vonsetamig works in the body * How much vonsetamig is present in the blood * If vonsetamig works to lower levels of antibodies to HLA
Conditions
- Chronic Kidney Disease (CKD)
Interventions
VonsetamigDrug
Administered by intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse event(s) of interest (AEI) from the first dose through end of the safety observation periodTime frame: Up to approximately 6 weeks
- Incidence and severity of treatment-emergent adverse events (TEAE)s from the first study drug dose up to the end of the studyTime frame: Up to 78 weeks
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
University of California Irvine
Orange, California
Connie Frank Transplant Center at UCSF
San Francisco, California
Yale University of Medicine
New Haven, Connecticut
Medstar Georgetown Transplant Institute - 2-PHC
Washington D.C., District of Columbia
Comprehensive Transplant Center
Chicago, Illinois
John Hopkins Hospital
Baltimore, Maryland
University of Minnesota
Minneapolis, Minnesota
New York University Langone Health
New York, New York
Penn Transplant Institute
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.